Empowered Patient Podcast

Sonia Garcia, Co-Founder and Chief Growth Officer at Amae Health, an integrated care company specializing in the treatment of severe mental illness that operates community-oriented clinics to deliver comprehensive psychiatry-led care. They provide continuity of care across multiple acuity levels, recognizing these conditions require long-term management. Amae is also advancing psychiatric care through research and partnerships by deploying wearables for health monitoring and investigating biomarkers and pharmacogenomics to improve treatment outcomes.

Sonia explains, "Amae Health is an integrated care company that exists to treat the most complex mentally ill. So those that are suffering from schizophrenia, bipolar disorder, major depressive disorder. And we do so through these community-oriented clinics that deliver comprehensive care that's psychiatry-led, but also incorporates therapy, primary care, social services, peer support specialists, dieticians for a lot of nutrition guidance, and health coaching. Then clinic care coordinators manage all the in-between things that need to happen to get somebody back on track and living a healthy, stable life."

"Another core pillar within the company that I'll just add is getting into technical research and innovation, with lots of work we can do to uncover what is causing this, what interventions we can deploy. How can we partner with others in the ecosystem, whether that's pharma or life sciences, to advance psychiatric care and see if we can get towards putting many of these conditions into remission?"

#AmaeHealth #MentalHealthCare #SevereMentalIllness #IntegratedCare #MetabolicPsychiatry #Schizophrenia #BipolarDisorder #ValueBasedCare #ContinuityOfCare #HealthcareInnovation #Psychiatry

amaehealth.com

Listen to the podcast here

Sonia Garcia, Co-Founder and Chief Growth Officer at Amae Health, an integrated care company specializing in the treatment of severe mental illness that operates community-oriented clinics to deliver comprehensive psychiatry-led care. They provide continuity of care across multiple acuity levels, recognizing these conditions require long-term management. Amae is also advancing psychiatric care through research and partnerships by deploying wearables for health monitoring and investigating biomarkers and pharmacogenomics to improve treatment outcomes.

Sonia explains, "Amae Health is an integrated care company that exists to treat the most complex mentally ill. So those that are suffering from schizophrenia, bipolar disorder, major depressive disorder. And we do so through these community-oriented clinics that deliver comprehensive care that's psychiatry-led, but also incorporates therapy, primary care, social services, peer support specialists, dieticians for a lot of nutrition guidance, and health coaching. Then clinic care coordinators manage all the in-between things that need to happen to get somebody back on track and living a healthy, stable life."

"Another core pillar within the company that I'll just add is getting into technical research and innovation, with lots of work we can do to uncover what is causing this, what interventions we can deploy. How can we partner with others in the ecosystem, whether that's pharma or life sciences, to advance psychiatric care and see if we can get towards putting many of these conditions into remission?"

#AmaeHealth #MentalHealthCare #SevereMentalIllness #IntegratedCare #MetabolicPsychiatry #Schizophrenia #BipolarDisorder #ValueBasedCare #ContinuityOfCare #HealthcareInnovation #Psychiatry

amaehealth.com

Download the transcript here

Sarah Lowe, Global Clinical Operations Director at XVIVO, develops technologies to preserve, assess, and transport organs for transplantation. With advanced assessment of donor lungs, the mission is to evaluate marginal organs better to address the critical challenge that only 2 out of 10 available lungs are currently accepted for transplant. With their first in-house ex vivo lung perfusion program, the goal is to increase organ utilization and expand access to transplants.

Sarah explains, "At XVIVO, our vision really is that nobody should die waiting for a new organ. As a company, we develop technologies that allow our clinicians to preserve, assess, and transport organs. So, in doing so, we're able to be part of the solution by helping increase the number of organs available for transplantation. In my role at XVIVO, I get to work closely with clinical teams and partners to support the implementation of our technologies and their programs, not only in the US but around the world. So really everything that we do is centered around helping more patients receive those lifesaving transplants."

"So this collaboration is so incredibly important, not only for XVIVO. I think for the transplant community as a whole, it brings advanced lung assessment directly into the organ recovery process. XVIVO lung perfusion- you'll hear me say EVLP. It is placed into the workflow at the organ procurement organization level rather than in a separate step later in transplantation."

"So Indiana Donor Network, I'll call it IDN, is the first organ recovery organization in the US that has an in-house lung perfusion program. And through this partnership, IDN can assess donor lungs using EVLP before transplantation decisions are finalized. So for us, it does matter for a few reasons. And I think it's important to emphasize that two in 10 lungs are transplanted, which means that 80% of them are declined."

#XVIVO #OrganTransplantation #HealthcareInnovation #MedTech #PatientOutcomes #TransplantMedicine #LungTransplant #EVLP #OrganDonation #TransplantInnovation #IndianaDonorNetwork #PerfusionSolution #HealthcareInnovation #OPO #PatientCare

XVIVOgroup.com

Listen to the podcast here

Sarah Lowe, Global Clinical Operations Director at XVIVO, develops technologies to preserve, assess, and transport organs for transplantation. With advanced assessment of donor lungs, the mission is to evaluate marginal organs better to address the critical challenge that only 2 out of 10 available lungs are currently accepted for transplant. With their first in-house ex vivo lung perfusion program, the goal is to increase organ utilization and expand access to transplants.

Sarah explains, "At XVIVO, our vision really is that nobody should die waiting for a new organ. As a company, we develop technologies that allow our clinicians to preserve, assess, and transport organs. So, in doing so, we're able to be part of the solution by helping increase the number of organs available for transplantation. In my role at XVIVO, I get to work closely with clinical teams and partners to support the implementation of our technologies and their programs, not only in the US but around the world. So really everything that we do is centered around helping more patients receive those lifesaving transplants."

"So this collaboration is so incredibly important, not only for XVIVO. I think for the transplant community as a whole, it brings advanced lung assessment directly into the organ recovery process. XVIVO lung perfusion- you'll hear me say EVLP. It is placed into the workflow at the organ procurement organization level rather than in a separate step later in transplantation."

"So Indiana Donor Network, I'll call it IDN, is the first organ recovery organization in the US that has an in-house lung perfusion program. And through this partnership, IDN can assess donor lungs using EVLP before transplantation decisions are finalized. So for us, it does matter for a few reasons. And I think it's important to emphasize that two in 10 lungs are transplanted, which means that 80% of them are declined."

#XVIVO #OrganTransplantation #HealthcareInnovation #MedTech #PatientOutcomes #TransplantMedicine #LungTransplant #EVLP #OrganDonation #TransplantInnovation #IndianaDonorNetwork #PerfusionSolution #HealthcareInnovation #OPO #PatientCare

XVIVOgroup.com

Download the transcript here

Vin Singh, Founder, Chairman, and CEO of Bullfrog AI, is applying proprietary AI technology to drug development, with a focus on drug target discovery and phase three clinical trials. The company's platform is derived from the Johns Hopkins University Applied Physics Lab and is designed to pinpoint drug targets, identify the root causes of disease, and match patients to appropriate treatments based on genetic profiles. Bullfrog AI aims to reduce clinical trial timelines, improve success rates, identify more accurate biomarkers, and improve patient outcomes.

Vin explains, "We are in the AI innovator category, and we're applying our proprietary platform to the challenges that exist in the world of drug development for pharmaceutical and biotech companies. Primarily our focus is on the first and the last stage of that process. So the first stage is what you call drug target discovery. So when you take a medication, it targets something in your body. So we're trying to identify novel targets that we believe are the root cause of certain diseases. And then we are also focused on the final stage, which is phase three clinical trials. That's where we have our experience. And that's obviously a very critical and pivotal point in the process and the final stage of a long 10- to 15-year, one- to two-billion-dollar drug development process."

"You need to have the right tool for a certain problem and then data, and they go together. I think on the data side, getting access to rich, deep data sets is critical. And fortunately, the cost to generate that type of data has come down pretty significantly over the past, say, 10 years. So now, for example, we have a project where we have brain data, and it's the type of data where you can really make discoveries and insights and so forth. And so that's a really critical part of this process. The other part is: what tool do you have, and what problem are you trying to solve? Our technology is unique. I'd say most companies use technology that comes from NVIDIA and AWS. So they're all kind of using the same tools from the same toolbox."

"Our technology comes from Johns Hopkins University Applied Physics Lab, which is a world-renowned institution. We have IP around our platform, and we've continued to innovate over the years. It definitely has unique capabilities, and it is specifically designed for the types of problems that exist in drug development."

#BullFrogAI $BFRG, #AI, #AIinBiotech, #MachineLearning, #DrugDevelopment #AIinHealthcare #PrecisionMedicine #Neuropsychiatry #Oncology #DigitalHealth #ClinicalTrials #Biomarkers #bfLEAP

bullfrogai.com

Listen to the podcast here

Vin Singh, Founder, Chairman, and CEO of Bullfrog AI, is applying proprietary AI technology to drug development, with a focus on drug target discovery and phase three clinical trials. The company's platform is derived from the Johns Hopkins University Applied Physics Lab and is designed to pinpoint drug targets, identify the root causes of disease, and match patients to appropriate treatments based on genetic profiles. Bullfrog AI aims to reduce clinical trial timelines, improve success rates, identify more accurate biomarkers, and improve patient outcomes.

Vin explains, "We are in the AI innovator category, and we're applying our proprietary platform to the challenges that exist in the world of drug development for pharmaceutical and biotech companies. Primarily our focus is on the first and the last stage of that process. So the first stage is what you call drug target discovery. So when you take a medication, it targets something in your body. So we're trying to identify novel targets that we believe are the root cause of certain diseases. And then we are also focused on the final stage, which is phase three clinical trials. That's where we have our experience. And that's obviously a very critical and pivotal point in the process and the final stage of a long 10- to 15-year, one- to two-billion-dollar drug development process."

"You need to have the right tool for a certain problem and then data, and they go together. I think on the data side, getting access to rich, deep data sets is critical. And fortunately, the cost to generate that type of data has come down pretty significantly over the past, say, 10 years. So now, for example, we have a project where we have brain data, and it's the type of data where you can really make discoveries and insights and so forth. And so that's a really critical part of this process. The other part is: what tool do you have, and what problem are you trying to solve? Our technology is unique. I'd say most companies use technology that comes from NVIDIA and AWS. So they're all kind of using the same tools from the same toolbox."

"Our technology comes from Johns Hopkins University Applied Physics Lab, which is a world-renowned institution. We have IP around our platform, and we've continued to innovate over the years. It definitely has unique capabilities, and it is specifically designed for the types of problems that exist in drug development."

#BullFrogAI $BFRG, #AI, #AIinBiotech, #MachineLearning, #DrugDevelopment #AIinHealthcare #PrecisionMedicine #Neuropsychiatry #Oncology #DigitalHealth #ClinicalTrials #Biomarkers #bfLEAP

bullfrogai.com

Download the transcript here

Dr. Greg Carroll, emergency physician and Co-Founder and CEO of ClinNEXUS, a data-first healthcare company addressing social drivers of health in underserved communities by breaking down data silos. Integrating clinical information with social, behavioral, and environmental factors and using AI to augment human care coordinators enables them to identify patient needs proactively and provide personalized support. The model emphasizes building trust through in-person engagement while leveraging digital tools to enhance the care manager's ability to process complex data and deliver real-time insights.

Greg explains, "We're a data-first company that is focused on improving healthcare outcomes for underserved communities. That's pretty broad. But if you think about traditional healthcare, especially in the United States, if you look at 20% of patients or individuals driving about 80% of costs in healthcare. And traditional healthcare has not been able to really put a dent in this over time. And really the reason is that traditional healthcare has not addressed the true drivers of people's health, especially in underserved communities."

"Traditional healthcare has not done a good job of addressing those non-clinical issues, and it's done an even worse job of orchestrating and ensuring that across all those dimensions, we're addressing people's health. And so, in terms of the mission, it's about breaking down the silos in people's care and in the data available to those who support them. Making sure we're looking at all dimensions of people's health and helping them navigate to live happier, healthier lives, especially for communities facing many of the challenges I've mentioned."

#ClinNEXUS #HealthcareInnovation #PopulationHealth #SocialDriversOfHealth #CareCoordination #AIinHealthcare #Medicaid #ValueBasedCare

clinNexus.com

Listen to the podcast here

Dr. Greg Carroll, emergency physician and Co-Founder and CEO of ClinNEXUS, a data-first healthcare company addressing social drivers of health in underserved communities by breaking down data silos. Integrating clinical information with social, behavioral, and environmental factors and using AI to augment human care coordinators enables them to identify patient needs proactively and provide personalized support. The model emphasizes building trust through in-person engagement while leveraging digital tools to enhance the care manager's ability to process complex data and deliver real-time insights.

Greg explains, "We're a data-first company that is focused on improving healthcare outcomes for underserved communities. That's pretty broad. But if you think about traditional healthcare, especially in the United States, if you look at 20% of patients or individuals driving about 80% of costs in healthcare. And traditional healthcare has not been able to really put a dent in this over time. And really the reason is that traditional healthcare has not addressed the true drivers of people's health, especially in underserved communities."

"Traditional healthcare has not done a good job of addressing those non-clinical issues, and it's done an even worse job of orchestrating and ensuring that across all those dimensions, we're addressing people's health. And so, in terms of the mission, it's about breaking down the silos in people's care and in the data available to those who support them. Making sure we're looking at all dimensions of people's health and helping them navigate to live happier, healthier lives, especially for communities facing many of the challenges I've mentioned."

#ClinNEXUS #HealthcareInnovation #PopulationHealth #SocialDriversOfHealth #CareCoordination #AIinHealthcare #Medicaid #ValueBasedCare

clinNexus.com

Download the transcript here

Susan Wood, CEO of VIDA, develops AI-driven imaging-based biomarkers that quantitatively measure biological processes and disease states using imaging modalities such as CT, MRI, PET, and ultrasound. Unlike traditional visual image analysis, VIDA's technology extracts approximately 25,000 measurements per imaging timepoint, enabling detection of therapeutic responses at the sub-millimeter level. This convergence of advanced scanner technology, high-quality imaging data, and AI-powered analysis represents a significant new frontier in precision medicine and drug development.

Susan explains, "I'll start with what VIDA brings in. Our background has been the development and validation of AI-driven imaging-based biomarkers. I'll start by defining a biomarker, specifically an imaging-based biomarker. It's a quantitative measurement derived from an imaging modality. An imaging modality can be a CT scan, an MRI, a PET scan, or an ultrasound, and the measurement reflects a biological process, a disease state, or a response to therapy. VIDA's formation was focused on the production and validation of those imaging-based biomarkers and on incorporating them into provider-based clinical workflows as well as clinical trial or drug development workflows."

"I would say that in general, traditionally radiology has relied on radiologic images, those imaging modalities have been read visually. And if you read an image visually, there's just a fraction of information that you can get from those images versus reading them with these AI-generated processes. So there's less than 1% of that image you'll be able to understand the extent and the complexity of the measurements that image can offer. We read, or we combine that visual reading with a highly quantitative process. So for each imaging time point, we'll measure 25,000 measurements per imaging time point. Obviously that's well beyond what a human eye could do just from an efficiency standpoint, but certainly from a precision standpoint, they wouldn't be able to measure that level of precision in the imaging by an eyeball alone."

#VIDA #AI #DigitalBiomarkers #MedicalImaging #Radiology #ClinicalTrials #DrugDevelopment #PrecisionMedicine #HealthcareInnovation #RespiratoryCare

vidalung.ai

Listen to the podcast here

Susan Wood, CEO of VIDA, develops AI-driven imaging-based biomarkers that quantitatively measure biological processes and disease states using imaging modalities such as CT, MRI, PET, and ultrasound. Unlike traditional visual image analysis, VIDA's technology extracts approximately 25,000 measurements per imaging timepoint, enabling detection of therapeutic responses at the sub-millimeter level. This convergence of advanced scanner technology, high-quality imaging data, and AI-powered analysis represents a significant new frontier in precision medicine and drug development.

Susan explains, "I'll start with what VIDA brings in. Our background has been the development and validation of AI-driven imaging-based biomarkers. I'll start by defining a biomarker, specifically an imaging-based biomarker. It's a quantitative measurement derived from an imaging modality. An imaging modality can be a CT scan, an MRI, a PET scan, or an ultrasound, and the measurement reflects a biological process, a disease state, or a response to therapy. VIDA's formation was focused on the production and validation of those imaging-based biomarkers and on incorporating them into provider-based clinical workflows as well as clinical trial or drug development workflows."

"I would say that in general, traditionally radiology has relied on radiologic images, those imaging modalities have been read visually. And if you read an image visually, there's just a fraction of information that you can get from those images versus reading them with these AI-generated processes. So there's less than 1% of that image you'll be able to understand the extent and the complexity of the measurements that image can offer. We read, or we combine that visual reading with a highly quantitative process. So for each imaging time point, we'll measure 25,000 measurements per imaging time point. Obviously that's well beyond what a human eye could do just from an efficiency standpoint, but certainly from a precision standpoint, they wouldn't be able to measure that level of precision in the imaging by an eyeball alone."

#VIDA #AI #DigitalBiomarkers #MedicalImaging #Radiology #ClinicalTrials #DrugDevelopment #PrecisionMedicine #HealthcareInnovation #RespiratoryCare

vidalung.ai

Download the transcript here